POLIVY Drug Insight and Market Forecast - 2032

This “POLIVY Drug Insight and Market Forecast – 2032” report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the POLIVY for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the POLIVY for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary

POLIVY (polatuzumab vedotin-piiq) is a CD79b-directed antibody-drug conjugate (ADC) consisting of three components: the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; the small molecule anti-mitotic agent MMAE; and a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-amino benzyloxy carbonyl (mc-VC-PAB) that covalently attaches MMAE to the polatuzumab antibody. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell-specific surface protein component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable the intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis. POLIVY is being developed by Roche using Seagen ADC technology and is being investigated for treating several types of NHL.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the POLIVY description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on POLIVY regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POLIVY research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around POLIVY.
• The report contains forecasted sales of POLIVY for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for POLIVY in DLBCL.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publishing team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POLIVY Analytical Perspective

In-depth POLIVY Market Assessment

This report provides a detailed market assessment of POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

POLIVY Clinical Assessment

The report provides the clinical trials information of POLIVY for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POLIVY dominance.
• Other emerging products for DLBCL are expected to give tough market competition to POLIVY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POLIVY in DLBCL.
• Our in-depth analysis of the forecasted sales data of POLIVY from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POLIVY in DLBCL.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of POLIVY?
• What is the clinical trial status of the study related to POLIVY in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POLIVY development?
• What are the key designations that have been granted to POLIVY for DLBCL?
• What is the forecasted market scenario of POLIVY for DLBCL?
• What are the forecasted sales of POLIVY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to POLIVY for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

This product will be delivered within 2 business days.